Ensol Biosciences Inc

Ensol Biosciences Inc operates with a liquidity position that is medium risk, as indicated by a current ratio of 1.7 and a negative net cash position after subtracting total debt. The company holds KRW 1,065,175,170 in cash and equivalents, but this is insufficient to cover its long-term debt of KRW 8,311,059,050. The debt-to-equity ratio of 0.61 suggests a moderate reliance on debt financing, but the negative operating and free cash flows of KRW -6,672,138,760 and KRW -4,915,069,990, respectively, indicate ongoing cash burn. Profitability metrics are severely negative, with a return on equity of -39.32% and a return on assets of -16.85%. These figures are well below the typical thresholds for pharmaceutical firms, which often require positive ROIC and ROE to justify R&D investment. The company’s operating income of KRW -7,189,008,370 and net income of KRW -5,335,727,080 highlight a significant loss-making position. The company’s revenue of KRW 25,056,000 is derived from a mix of R&D activities and services such as synthesis and purification, as well as consulting on breeding information systems. However, the disclosed segments do not provide geographic breakdowns, and the company does not report revenue concentration by region or product line. Growth trajectory is not evident from the current financials, with no clear indication of revenue expansion or margin improvement. The company’s capital expenditures of KRW -30,869,910 suggest minimal investment in physical assets, which is typical for early-stage biotech firms focused on R&D. However, the absence of positive revenue growth or margin expansion raises questions about the company’s ability to scale. Risk factors include liquidity constraints and the potential for dilution, though the dilution risk is currently assessed as low. The company has not issued additional shares recently, and the basic and diluted share counts are identical at 13,372,948 shares. However, the negative net cash position and ongoing losses could pressure the company to raise capital through equity issuance in the future. Recent events include the continued development of multiple drug candidates, including 'Peniel2000' for degenerative disc disease and 'Engedi1000' for knee osteoarthritis. The company has also expanded into canine osteoarthritis therapy and Alzheimer’s disease treatment. No recent filings or transcripts have been disclosed that indicate significant changes in strategy or regulatory progress.